Immune checkpoint blockade, which blocks inhibitory signals of T cell activation, has shown
tremendous success in treating cancer, although success still remains limited to a fraction of …

Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …

The binding of T cell immune checkpoint proteins programmed death 1 (PD-1) and cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) to their ligands allows immune evasion by …

Sample multiplexing facilitates scRNA-seq by reducing costs and identifying artifacts such
as cell doublets. However, universal and scalable sample barcoding strategies have not …

Conditional gene expression has greatly facilitated the examination of the functions of
particular gene products. Using the Cre/lox P switching expression system, we plan to …

Melanoma treatment has been revolutionized by antibody-based immunotherapies. IFNγ
secretion by CD8+ T cells is critical for therapy efficacy having anti-proliferative and pro …

Tumours can escape T‐cell responses by losing major histocompatibility complex
(MHC)/human leucocyte antigen (HLA) class I molecules. In the early stages of cancer …

Neoantigens are newly formed peptides created from somatic mutations that are capable of
inducing tumor-specific T cell recognition. Recently, researchers and clinicians have …

It has become evident that tumor-induced immuno-suppressive factors in the tumor
microenvironment play a major role in suppressing normal functions of effector T cells …